AH-300

AH-300 is a preclinical-stage small molecule therapeutic being developed by Attillaps Holdings. It is part of the company's Acetylcholine Modulator (AChM) platform, which utilizes a multi-target mechanism to modulate cholinergic pathways and exert anti-Demodex activity. The drug is designed as a topical formulation using the FDA's 505(b)(2) regulatory pathway, indicating it is a repositioned version of a previously approved drug. AH-300 is intended to treat the "Demodex-associated inflammatory and autoimmune disease spectrum" (DCIDS), including rosacea, blepharitis, cutaneous lupus, and acne, as well as serving as an adjunctive treatment for rheumatoid arthritis and other autoimmune conditions.

Other names

AH-300AH300AH 300